Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07914946
NA

Trigonelline Plus Sufentanil for Postoperative Analgesia After Laparoscopic Hysterectomy: A Randomized Controlled Clinical Trial

Sponsor: Hainan Medical College

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to learn whether the combination of trigonelline and sufentanil can better control postoperative pain in adult women undergoing gynecologic laparoscopic surgery, while reducing discomforts such as nausea and vomiting. It also aims to explore whether using both drugs together is safer than using either one alone. The main questions it seeks to answer are: Does trigonelline combined with sufentanil result in less pain for participants after surgery? Does the combination reduce the occurrence of nausea, vomiting, dizziness, and other side effects? Researchers will compare three different postoperative pain relief plans to determine which one works best and causes the fewest side effects: Sufentanil group: receiving only sufentanil (a commonly used strong pain-relieving medicine) Trigonelline group: receiving only trigonelline (a newer type of pain-relieving medicine that may cause fewer stomach problems) Combination group: receiving both medicines together, each at half the usual dose Participants will: Sign an informed consent form before surgery agreeing to take part in this study Receive pain relief through a patient-controlled intravenous analgesia (PCIA) pump connected to a vein in the hand or arm after surgery (the pump can deliver medicine automatically, and participants may also press a button to request extra doses) Be asked by the medical team about their pain level at several time points within 48 hours after surgery Tell the researchers if they feel any discomfort such as nausea, dizziness, sleepiness, or itching

Official title: A Prospective, Randomized, Active-Controlled, Single-Center, Single-Blind Clinical Trial Comparing Trigonelline Monotherapy, Sufentanil Monotherapy, and Trigonelline-Sufentanil Combination Therapy for Patient-Controlled Intravenous Analgesia (PCIA) After Gynecologic Laparoscopic Hysterectomy or Myomectomy

Key Details

Gender

FEMALE

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

165

Start Date

2026-05-01

Completion Date

2026-08-30

Last Updated

2026-11-04

Healthy Volunteers

No

Interventions

DRUG

Sufentanil

Sufentanil citrate injection is a mu-opioid receptor agonist analgesic medication used for postoperative patient-controlled intravenous analgesia (PCIA) following gynecologic laparoscopic surgery (hysterectomy or myomectomy) in this study. In Arm 1 (Sufentanil Monotherapy), the dose is 2.0 micrograms per kilogram (μg/kg) of body weight. In Arm 3 (Combination Therapy), the dose is 1.0 μg/kg (combined with trigonelline 0.05 mg/kg). The drug is diluted to 100 milliliters with 0.9% sodium chloride injection and administered via PCIA pump with standardized settings: background infusion rate 2 mL/hour, bolus dose 0.5 mL, lockout interval 15 minutes. The PCIA pump is connected intravenously at the end of surgery before emergence from general anesthesia and continues for 48 hours postoperatively.

DRUG

Trigonelline

Trigonelline injection is a novel biased mu-opioid receptor agonist that provides effective analgesia with reduced beta-arrestin-mediated adverse effects, particularly gastrointestinal side effects such as nausea and vomiting, by preferentially activating G-protein signaling while minimizing beta-arrestin recruitment. In this study, it is used for postoperative patient-controlled intravenous analgesia (PCIA) following gynecologic laparoscopic surgery (hysterectomy or myomectomy). In Arm 2 (Trigonelline Monotherapy), the dose is 0.1 milligrams per kilogram (mg/kg) of body weight. In Arm 3 (Combination Therapy), the dose is 0.05 mg/kg (combined with sufentanil 1.0 μg/kg). The drug is diluted to 100 milliliters with 0.9% sodium chloride injection and administered via PCIA pump with standardized settings: background infusion rate 2 mL/hour, bolus dose 0.5 mL, lockout interval 15 minutes. The PCIA pump is connected intravenously at the end of surgery before emergence from general anesthesia

Locations (1)

No. 368, Yehai Avenue, Longhua District, Haikou, Hainan, P.R. China

Haikou, Hainan, China